BioXcel Therapeutics, Inc.
NASDAQ · us_market
No AI summary generated yet for this ticker.
BioXcel Therapeutics, Inc., together with its subsidiary, OnkosXcel Therapeutics LLC, operates as a biopharmaceutical company that utilizes artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology in the United States. The company IGALMI, a sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. It also develops its neuroscience candidate, BXCL501, which is an investigational, proprietary, orally dissolving sublingual film formulation of dexmedetomidine in Phase 3 trial for the treatment of agitation associated with bipolar disorders, schizophrenia, and Alzheimer's disease, as well as opioid use disorder, alcohol use disorder with comorbid post-traumatic stress disorder, and acute stress disorder; and its immune-oncology candidate, BXCL701, which is an investigational oral innate immune activator that has completed Phase 1b/2a trial for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors. In addition, the company engages in the development of BXCL502 for the treatment of stress-related neuropsychiatric symptoms in dementia and other stress-related disorders; BXCL503, a drug candidate to target apathy in dementia; and BXCL504, which has the potential to address apathy and aggression in dementia. The company has collaborations with Columbia University, Yale University Medical School, and University of North Carolina for the development of BXCL501. BioXcel Therapeutics, Inc. was incorporated in 2017 and is headquartered in New Haven, Connecticut.
BioXcel Therapeutics, Inc. (NASDAQ:BTAI), a biopharmaceutical company built on artificial intelligence ("AI") to develop transformative medicines in neuroscience, today announced the presentation of new positive data
BioXcel Therapeutics (BTAI) delivered earnings and revenue surprises of +8.48% and -28.97%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
BioXcel Therapeutics (BTAI) delivered earnings and revenue surprises of +8.48% and -28.97%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
FDA accepted sNDA for IGALMI® use in at-home (outpatient) setting; set Nov. 14, 2026, as PDUFA date Advancing BXCL501 as a potential acute treatment for agitation associated with Alzheimer’s dementia Evaluating strategic options with an advisor to maximize shareholder value and advance the commercial and development plans for IGALMI NEW HAVEN, Conn., May 15, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company built on artificial intelligence (“AI”) to
FDA accepted sNDA for IGALMI® use in at-home setting; set Nov. 14, 2026, as PDUFA date Advancing BXCL501 as a potential acute treatment for agitation associated with Alzheimer’s dementia ...
CorMedix (CRMD) delivered earnings and revenue surprises of +24.64% and +16.00%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
CorMedix (CRMD) delivered earnings and revenue surprises of +24.64% and +16.00%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Verastem (VSTM) delivered earnings and revenue surprises of 0.00% and -16.09%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Verastem (VSTM) delivered earnings and revenue surprises of 0.00% and -16.09%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
BioXcel Therapeutics (BTAI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BioXcel Therapeutics (BTAI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BioXcel Therapeutics, Inc. (BTAI) Discusses Commercial Launch Strategy and Market Opportunity for IGALMI in At-Home Setting April 23, 2026 2:00 PM...
Presentation Operator MessageOperator Greetings, and welcome to the BioXcel Therapeutics webcast. [Operator Instructions] It is now my pleasure to introduce Vimal Mehta, Chief Executive Officer and...
We recently compiled a list of the 10 Best Beaten Down Stocks to Invest in According to Analysts. BioXcel Therapeutics, Inc. is one of the best 52-week low stocks. TheFly reported on April 2 that H.C. Wainwright lowered its price target on BTAI to $5 from $6 while maintaining a Buy rating. The firm attributed […]
We recently compiled a list of the 10 Best Beaten Down Stocks to Invest in According to Analysts. BioXcel Therapeutics, Inc. is one of the best 52-week low stocks. TheFly reported on April 2 that H.C. Wainwright lowered its price target on BTAI to $5 from $6 while maintaining a Buy rating. The firm attributed […]
Live event to be held on Thursday, April 23, at 2:00 p.m. ET Company focused on advancing launch strategy ahead of November 14 PDUFA target action date NEW HAVEN, Conn., April 17, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company built on artificial intelligence (“AI”) to develop transformative medicines in neuroscience, today announced it will host a virtual event on Thursday, April 23, from 2:00 to 3:00 p.m. ET. The event will center on the Company
BioXcel Therapeutics is back in focus after a slight trim to one fair value estimate to US$14.00 from US$14.25, while another piece of Street research sets a separate price target at US$17 and a more cautious voice cuts its target to US$6 from US$10. These moves reflect the ongoing split between analysts who highlight the long term potential of BXCL501 and those who are more concerned about equity dilution and funding pressure. Read on to see how to track this evolving narrative and what it...
BioXcel Therapeutics is back in focus after a slight trim to one fair value estimate to US$14.00 from US$14.25, while another piece of Street research sets a separate price target at US$17 and a more cautious voice cuts its target to US$6 from US$10. These moves reflect the ongoing split between analysts who highlight the long term potential of BXCL501 and those who are more concerned about equity dilution and funding pressure. Read on to see how to track this evolving narrative and what it...
DoW-funded Phase 2a trial led by University of North Carolina at Chapel Hill (UNC) Institute for Trauma Recovery Positive outcomes from trial can potentially impact Veteran Affairs/Department of War Clinical Practice Guidelines for management of acute stress reactions (ASR) NEW HAVEN, Conn., April 08, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company built on artificial intelligence (“AI”) to develop transformative medicines in neuroscience, today an
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| StateStreet | passive | 92.1K | $123.44K | 0.00% | Added+45.7% | 2026-03-31 |
| FidelityFMR | fundamental | 90.3K | $121.00K | 0.00% | Unchanged | 2026-03-31 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-05-15 | -0.48 | -0.54 | -11.34% |
| 2026-03-26 | -0.68 | — | — |
| 2025-11-12 | -1.34 | -2.16 | -61.48% |
| 2025-08-12 | -1.56 | -2.45 | -56.72% |
| 2025-05-12 | -3.04 | -1.50 | +50.66% |
| 2025-03-27 | -5.14 | -3.56 | +30.73% |
| 2024-11-14 | -7.68 | -5.12 | +33.33% |
| 2024-08-06 | -10.99 | -3.36 | +69.42% |
| 2024-05-09 | -11.52 | -13.92 | -20.83% |
| 2024-03-12 | -12.72 | -12.16 | +4.40% |
| 2023-11-14 | -20.00 | -25.32 | -26.62% |
| 2023-08-14 | -27.68 | -29.28 | -5.77% |
| 2023-05-09 | -25.37 | -29.44 | -16.06% |
| 2023-03-09 | -22.61 | -31.20 | -37.99% |
| 2022-11-10 | -20.84 | -23.84 | -14.39% |
| 2022-08-09 | -18.89 | -21.60 | -14.38% |
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| BTAI | -2.50% | -26.88% | -26.88% | -0.85% |
| XLV | +2.97% | -4.64% | -3.44% | +12.69% |
| Alpha (stock − sector) | -5.47% | -22.24% | -23.43% | -13.54% |